Pneumococcal polysaccharide conjugate vaccine (adsorbed)
Also known as: Synflorix · Vaxneuvance
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, pneumococcal polysaccharide conjugate vaccine (adsorbed) is indicated for active immunisation against invasive disease and acute otitis media caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age. It is also indicated in the European Union for active immunisation to prevent invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in individuals from six weeks to less than 18 years of age, and for invasive disease and pneumonia in individuals 18 years of age and older. The vaccine has an approved indication for pneumonia due to Streptococcus pneumoniae.
Source: European Medicines Agency (EMA), Synflorix — EPAR, 19/05/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Vaxneuvance — EPAR, 16/07/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- EMA
- EMEA/H/C/000973, EMEA/H/C/005477
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Synflorix
Active immunisation against invasive disease and acute otitis media caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age. See sections 4.4 and 5.1 in product information for information on protection against specific pneumococcal serotypes. The use of Synflorix should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as the variability of serotype epidemiology in different geographical areas.
Source: European Medicines Agency (EMA), Synflorix — EPAR, 19/05/2026. © European Medicines Agency.
Document date: 19/05/2026 · Official document →
EMA (EU) Vaxneuvance
Vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. Vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes. The use of Vaxneuvance should be in accordance with official recommendations.
Source: European Medicines Agency (EMA), Vaxneuvance — EPAR, 16/07/2026. © European Medicines Agency.
Document date: 16/07/2026 · Official document →
Related terms in the cited sources
Has an official indication for
- Pneumococcal pneumonia Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Pneumococcal polysaccharide conjugate vaccine (adsorbed) approved for in the European Union?
Active immunisation against invasive disease and acute otitis media caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age. See sections 4.4 and 5.1 in product information for information on protection against specific pneumococcal serotypes. The use of Synflorix should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as the variability of serotype epidemiology in different geographical areas. (Source: European Medicines Agency (EMA), Synflorix — EPAR, 19/05/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Synflorix — EPAR, 19/05/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Vaxneuvance — EPAR, 16/07/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.